Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVP-923 for Agitation in Alzheimer's Disease
NCT01584440Phase 2Completed
- Sponsor
- Avanir Pharmaceuticals
- Start
- Aug 2012
- Primary completion
- Jul 2014
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dextromethorphan + quinidine in Alzheimer's disease (AD), sponsored by Avanir Pharmaceuticals. Started Aug 2012; status: completed.
02
Drugs
dextromethorphan + quinidine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01584440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01584440.